Sekretētās miRNS - sekrēcijas mehānismi un iespējas tās izmantot kā biomarķierus vēža diagnostikā un prognostikā
Date
2013
Authors
Andrējeva, Diāna
Journal Title
Journal ISSN
Volume Title
Publisher
Latvijas Universitāte
Abstract
Plaušu vēzis ir visbiežāk sastopamais un viens no agresīvākajiem ļaundabīgajiem audzējiem, no kura ik gadu pasaulē mirst ~1.37 miljoni cilvēku. Neinvazīvi biomarķieru testi tā diagnostikai, monitoringam un terapijas efektivitātes prognozēšanai dotu būtisku ieguldījumu vēža agrākā atklāšanā un ārstēšanas efektivitātes uzlabošanā. Zināms, ka vēža-asociētas miRNS var nonākt asinīs pat vairākus gadus pirms klīnisko simptomu parādīšanās un, iespējams, ka to profils atspoguļo audzējā notiekošos procesus, tādēļ seruma/plazmas miRNS varētu būt ļoti labi biomarķieri. Šī darba mērķis bija noskaidrot faktorus, kas var ietekmēt miRNS daudzumu un stabilitāti asins paraugos un izstrādāt metodiku vēža šūnu sekretēto miRNS biomarķieru identificēšanai.
Lung cancer is the most common and one of the most aggressive cancers. Each year ~ 1,37 million people will die from it worldwide. Non-invasive biomarker tests for the diagnosis, monitoring and treatment effectiveness forecasting would contribute significantly to earlier cancer detection and improving the effectiveness of treatment. It is known that cancer-associated miRNA can enter the bloodstream several years before clinical symptoms and appears miRNA profile reflects the processes in tumor, so serum/plasma miRNA could be a very good biomarker. Therefore, the aim of this work is to identify the factors that may affects miRNA stability and profile in blood samples and develop an method for biomarker identification of cancer cell secreted miRNA.
Lung cancer is the most common and one of the most aggressive cancers. Each year ~ 1,37 million people will die from it worldwide. Non-invasive biomarker tests for the diagnosis, monitoring and treatment effectiveness forecasting would contribute significantly to earlier cancer detection and improving the effectiveness of treatment. It is known that cancer-associated miRNA can enter the bloodstream several years before clinical symptoms and appears miRNA profile reflects the processes in tumor, so serum/plasma miRNA could be a very good biomarker. Therefore, the aim of this work is to identify the factors that may affects miRNA stability and profile in blood samples and develop an method for biomarker identification of cancer cell secreted miRNA.
Description
Keywords
Bioloģija